4
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0000899243-22-011660
Options or other derivatives
- Chief Science Officer acquired 24,972 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Bausch Christoph Lawrence Chief Science Officer | 2022-03-16 | Grant or award · Employee Stock Option (right to buy) | +24,972 | 24,972 | D | ||
Loading xslF345X03/doc4.xml…